10-Q
Quarterly Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
41 line items · 2 periods
XBRL
| Item | Jun 30, 2025 | Dec 31, 2024 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 397,712,000 | 344,067,000 |
Marketable securities | 49,549,000 | 49,335,000 |
Accounts receivable, net | 49,977,000 | 87,862,000 |
Other receivables | 69,090,000 | 606,000 |
Bruker Corporation | 68,000,000 | — |
Inventory | 68,968,000 | 83,107,000 |
Prepaid expenses and other current assets | 20,365,000 | 19,410,000 |
Total current assets | 655,661,000 | 584,387,000 |
Property and equipment, net | 239,710,000 | 252,648,000 |
Operating lease right-of-use assets | 62,700,000 | 57,290,000 |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 14,714,000 | 15,671,000 |
Other noncurrent assets | 2,674,000 | 4,129,000 |
Total assets | 979,970,000 | 918,636,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 15,938,000 | 12,909,000 |
Accrued compensation and related benefits | 26,102,000 | 33,615,000 |
Accrued expenses and other current liabilities | 39,063,000 | 41,165,000 |
Deferred revenue | 21,449,000 | 20,658,000 |
Products and Services, Excluding Grant Revenue | 21,400,000 | — |
Operating lease liabilities | 9,669,000 | 9,286,000 |
Total current liabilities | 112,221,000 | 117,633,000 |
Operating lease liabilities, noncurrent | 77,075,000 | 73,327,000 |
Deferred revenue, noncurrent | 11,270,000 | 12,513,000 |
Other noncurrent liabilities | 6,125,000 | 5,029,000 |
Total liabilities | 206,691,000 | 208,502,000 |
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 2,000 | 2,000 |
Additional paid-in capital | 2,239,924,000 | 2,177,672,000 |
Accumulated deficit | (1,466,867,000) | (1,467,047,000) |
Accumulated other comprehensive income (loss) | 220,000 | (493,000) |
Total stockholders’ equity | 773,279,000 | 710,134,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,239,924,000 | 2,177,672,000 |
Accumulated Deficit | (1,466,867,000) | (1,467,047,000) |
Accumulated Other Comprehensive Income (Loss) | 220,000 | (493,000) |
Total liabilities and stockholders’ equity | 979,970,000 | 918,636,000 |